KEZAR LIFE SCIENCES INC (KZR) Stock News

USA - NASDAQ:KZR - US49372L2097 - Common Stock

4.22 USD

-0.18 (-4.09%)

Last: 10/10/2025, 8:40:18 PM

4.22 USD

0 (0%)

After Hours: 10/10/2025, 8:40:18 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

KZR Latest News, Press Relases and Analysis

All

Press Releases

24 days ago - By: Zacks Investment Research

All You Need to Know About Kezar Life Sciences (KZR) Rating Upgrade to Buy

a month ago - By: Kezar Life Sciences

Kezar Life Sciences to Participate in Two Upcoming Investor Conferences

2 months ago - By: The Motley Fool

Kezar Narrows Loss 37 Percent in Q2

2 months ago - By: Kezar Life Sciences, Inc.

Kezar Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update

3 months ago - By: Benzinga

FDA Lifts Pause On Kezar's Liver Drug Trial—Next Stop Lupus Study

a year ago - By: Benzinga

Looking Into Kezar Life Sciences's Recent Short Interest

a year ago - By: BusinessInsider

News Image

KZR Stock Earnings: Kezar Life Sciences Beats EPS for Q2 2024

a year ago - By: InvestorPlace

KZR Stock Earnings: Kezar Life Sciences Beats EPS for Q2 2024

3 months ago - By: Kezar Life Sciences, Inc.

Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis

5 months ago - By: Kezar Life Sciences, Inc.

Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference

5 months ago - By: Yahoo Finance - Mentions: PRME EHC NVDA NPCE ...

Citi Downgrades Prime Medicine (PRME) to Neutral, Cuts PT to $1.50 Due to Market Uncertainty

5 months ago - By: Zacks Investment Research

Kezar Life Sciences (KZR) Upgraded to Buy: What Does It Mean for the Stock?

5 months ago - By: Kezar Life Sciences, Inc.

Kezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update

7 months ago - By: Kezar Life Sciences, Inc.

Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results

7 months ago - By: Kezar Life Sciences, Inc.

Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025

8 months ago - By: Kezar Life Sciences, Inc.

Kezar Life Sciences to Present at Virtual KOL Event Hosted by William Blair on Zetomipzomib Clinical Development in Autoimmune Hepatitis and Provide a Safety Update from the PALIZADE Trial for Lupus Nephritis on February 27, 2025

a year ago - By: Kezar Life Sciences, Inc.

Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update

a year ago - By: Glancy Prongay & Murray LLP

Glancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR)

a year ago - By: Kezar Life Sciences

Kezar Life Sciences Announces 1-for-10 Reverse Stock Split

a year ago - By: Yahoo Finance

Penny Stock Kezar Life Sciences Rejects Acquisition Deal From Concentra Biosciences At $1.10/Share, Shelves Mid-Stage Lupus Nephritis Study

a year ago - By: Kezar Life Sciences

Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan

a year ago - By: Kezar Life Sciences, Inc.

Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update

a year ago - By: Kezar Life Sciences, Inc.

Kezar Confirms Receipt of Unsolicited, Non-Binding Acquisition Proposal

a year ago - By: Yahoo Finance

FDA Put Brakes On Penny Stock Kezar Life Sciences' Mid-Stage Study For Lead Development Candidate After Patient Deaths

a year ago - By: Kezar Life Sciences, Inc.

Kezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus Nephritis

a year ago - By: Kezar Life Sciences, Inc.

Kezar Life Sciences Announces Cessation of Enrollment and Dosing in the Phase 2b PALIZADE Trial of Zetomipzomib in Active Lupus Nephritis Patients

a year ago - By: Kezar Life Sciences, Inc.

Kezar Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

a year ago - By: Kezar Life Sciences, Inc.

Kezar Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update

a year ago - By: Kezar Life Sciences, Inc.

Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

a year ago - By: Kezar Life Sciences, Inc.

Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)